2015 Antineoplastics

Drugs that interfere with angiogenesis: BEVACIZUMAB

Example Question
  • humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF)

  • approved (in combination with 5-Fluorouracil) for first-line treatment of patients with metastatic colorectal cancer, lung cancer, breast cancer (controversial),
    • being investigated for use in many other cancers, particularly gliomas
    • also approved for use in macular degeneration and diabetic neuropathy
      • RANIBIZUMAB (which is promoted by the drug company as the preferred treatment) is a derivative of BEVACIZUMAB
        • check out the Wikipedia discussion of the off-label use of BEVACIZUMAB and the impacts of RANIBIZUMAB choice (under Non-oncologic uses)!

  • in addition to the side effects common to antibodies, BEVACIZUMAB can cause gastrointestinal perforation, wound dehiscence and hemoptysis, which can be fatal

  • there is concern that BEVACIZUMAB treatment could worsen coronary or peripheral artery disease by preventing the sprouting of new vessels
Email: Dr. Janet Fitzakerley | ©2015 University of Minnesota Medical School Duluth | Last modified: 11-apr-15 9:39 AM